

# Gianluca Gaidano

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4636564/gianluca-gaidano-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

685  
papers

29,532  
citations

85  
h-index

144  
g-index

712  
ext. papers

33,785  
ext. citations

5.7  
avg, IF

6.46  
L-index

#	Paper	IF	Citations
685	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 8	7	1
684	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.. <i>Advances in Hematology</i> , <b>2022</b> , 2022, 5581772	1.5	
683	Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model.. <i>American Journal of Hematology</i> , <b>2022</b> , ,	7.1	2
682	A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation.. <i>Nature Communications</i> , <b>2022</b> , 13, 2042	17.4	1
681	Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma. <i>HemaSphere</i> , <b>2022</b> , 6, e727	0.3	0
680	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1669-1680	21.7	20
679	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2021</b> ,	2.2	5
678	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	13
677	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , <b>2021</b> , 138, 48-48	2.2	0
676	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 115-115	2.2	0
675	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 4440-4440	2.2	
674	Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 372-372	2.2	5
673	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , <b>2021</b> , 138, 3746-3746	2.2	0
672	Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher Allele Burden in Patients With Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 777730	5.3	0
671	Precision Medicine in Systemic Mastocytosis. <i>Medicina (Lithuania)</i> , <b>2021</b> , 57,	3.1	2
670	Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
669	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , <b>2021</b> , 39, 326-335	13.5	3

668	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 73	7	3
667	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3695-3703	12.9	1
666	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. <i>Disease Markers</i> , <b>2021</b> , 2021, 8863053	3.2	9
665	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1810-1823	59.2	28
664	A randomized clinical study on the impact of Comprehensive Geriatric Assessment (CGA) based interventions on the quality of life of elderly, frail, onco-hematologic patients candidate to anticancer therapy: protocol of the ONCO-Aging study. <i>BMC Geriatrics</i> , <b>2021</b> , 21, 320	4.1	0
663	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E306-E310	7.1	3
662	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	5
661	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 3027-3036	2.2	15
660	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , <b>2021</b> , 137, 3507-3517	2.2	12
659	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 190-202	7.5	14
658	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
657	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , <b>2021</b> , 138, 2290-2293	2.2	3
656	Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 108-112	4.5	1
655	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , <b>2021</b> , 35, 235-238	10.7	11
654	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , <b>2021</b> , 106, 1079-1085	6.6	8
653	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. <i>Blood</i> , <b>2021</b> , 137, 646-660	2.2	22
652	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 755-757	1.9	4
651	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , <b>2021</b> , 137, 1365-1376	2.2	26

650	Investigational drugs for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 25-38	5.9	7
649	An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, 98-101	0.7	
648	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 493-499	3.8	1
647	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211042224	5.4	3
646	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E168-E171	7.1	5
645	Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e009375	6.4	9
644	Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. <i>Leukemia</i> , <b>2021</b> , 35, 2325-2331	10.7	3
643	Intravascular lymphoma: from vessels to genes. <i>Blood</i> , <b>2021</b> , 137, 1438-1439	2.2	1
642	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , <b>2021</b> ,	44.5	16
641	The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2021</b> , 27, 266-274	2.2	0
640	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2021</b> , 106, 2417-2426	6.6	20
639	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , <b>2021</b> , 127, 4421-4431	6.4	1
638	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2605-2616	2.2	4
637	Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2021</b> ,	6.6	4
636	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , <b>2021</b> , 39, 707-711	1.3	0
635	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 684621	5.3	1
634	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , <b>2021</b> , 5, e639	0.3	
633	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	1

632	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , <b>2020</b> , 135, 1859-1869	2.2	45
631	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 978-988	21.7	136
630	A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , <b>2020</b> , 105, e164-e168	6.6	4
629	Precision Medicine Management of Chronic Lymphocytic Leukemia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	16
628	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , <b>2020</b> , 105, 2592-2597	6.6	11
627	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
626	European education corridors: opportunity for academic solidarity. <i>Lancet</i> , <b>2020</b> , 395, 1343	4.0	2
625	Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , <b>2020</b> , 38, 406-408	1.3	2
624	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , <b>2020</b> , 135, 1244-1254	2.2	18
623	Biological and clinical implications of mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 448-456	6.6	35
622	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , <b>2020</b> , 136, 47-49	2.2	
621	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , <b>2020</b> , 136, 23-25	2.2	
620	Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Training/Validation Study. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	0
619	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	2
618	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 853-859	4.5	6
617	Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 24-25	2.2	2
616	Radiotherapy in COVID-19 patient affected by multiple myeloma: a case report.. <i>Translational Cancer Research</i> , <b>2020</b> , 9, 7662-7668	0.3	2
615	Reply to Aron P. Kater. <i>Haematologica</i> , <b>2020</b> , 105, e384	6.6	

614	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , <b>2020</b> , 29, 815-823	3.7	11
613	An update on: molecular genetics of high-risk chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 109-116	2.8	3
612	Targeting p53 in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , <b>2020</b> , 24, 1239-1250	4.4	6
611	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , <b>2020</b> , 12,	6.6	40
610	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. <i>Scientific Reports</i> , <b>2020</b> , 10, 20731	4.9	42
609	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , <b>2020</b> ,	24.4	96
608	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. <i>Expert Opinion on Orphan Drugs</i> , <b>2020</b> , 8, 329-342	1.1	2
607	Atypical Chronic Myeloid Leukemia: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	10
606	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8468-8479	4.8	8
605	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 92	7	5
604	Cerebrospinal fluid xanthochromia after pegasparginase hepatotoxicity in B-cell acute lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , <b>2020</b> , 8, 2293-2294	0.7	
603	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , <b>2020</b> , 4, e432	0.3	15
602	mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , <b>2020</b> , 105, 1604-1612	6.6	52
601	HIF-1 $\beta$ s over-expressed in leukemic cells from -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 1042-1054	6.6	23
600	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , <b>2020</b> , 34, 462-477	10.7	12
599	Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. <i>Hematological Oncology</i> , <b>2020</b> , 38, 204-206	1.3	2
598	Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. <i>Leukemia</i> , <b>2019</b> , 33, 1801-1805	10.7	4
597	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , <b>2019</b> , 81, 88-94	2.7	6

596	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 755-757	2.2	1
595	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , <b>2019</b> , 104, e558-e561	6.6	31
594	Liquid biopsy in lymphoma. <i>Haematologica</i> , <b>2019</b> , 104, 648-652	6.6	26
593	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , <b>2019</b> , 8, 2041-2055	4.8	40
592	Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , <b>2019</b> , 104, 1640-1647	6.6	16
591	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 330-334	4.5	4
590	Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 156-159	4.5	6
589	Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 478-487	4.5	5
588	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 988-1000	25.5	82
587	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 123-133	27.4	80
586	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , <b>2019</b> , 178, 699-713.e19	56.2	84
585	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , <b>2019</b> , 22, 1303-1310	3.3	8
584	XPO1 Mutations May Identify Binet C Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment. <i>Blood</i> , <b>2019</b> , 134, 1743-1743	2.2	2
583	Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 5454-5454	2.2	3
582	Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7521-7521	2.2	7
581	Early progression of disease (POD24) as survival predictor in MALT lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7548-7548	2.2	
580	Genome-wide promoter methylation of hairy cell leukemia. <i>Blood Advances</i> , <b>2019</b> , 3, 384-396	7.8	10
579	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , <b>2019</b> , 104, 1004-1015	10.15	14

578	Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2695-2706	7.5	12
577	Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 392-396	4.5	8
576	Methods for Measuring ctDNA in Lymphomas. <i>Methods in Molecular Biology</i> , <b>2019</b> , 1881, 253-265	1.4	5
575	Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 360-369	6.6	24
574	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , <b>2018</b> , 245, 61-73	9.4	15
573	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , <b>2018</b> , 36, 624-632	1.3	36
572	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , <b>2018</b> , 103, 849-856	6.6	12
571	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. <i>Hematological Oncology</i> , <b>2018</b> , 36, 600	1.3	7
570	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , <b>2018</b> , 103, 1209-1217	6.6	24
569	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , <b>2018</b> , 32, 1869-1873	10.7	8
568	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , <b>2018</b> , 29, 544-562	10.3	42
567	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2904-2910	1.9	5
566	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , <b>2018</b> , 32, 1803-1807	10.7	29
565	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e117-e126	14.6	52
564	ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. <i>Leukemia</i> , <b>2018</b> , 32, 1070-1080	10.7	93
563	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1266-1272	10.3	62
562	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , <b>2018</b> , 131, 2413-2425	2.2	122
561	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , <b>2018</b> , 29, 966-972	10.3	13



560	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 461-473	4.4	17
559	Biology and treatment of Richter syndrome. <i>Blood</i> , <b>2018</b> , 131, 2761-2772	2.2	87
558	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 25	7	18
557	Potential of BCL2 as a target for chronic lymphocytic leukemia treatment. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 391-402	2.8	6
556	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 693-695	4.5	1
555	Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. <i>Hematological Oncology</i> , <b>2018</b> , 36, 84-92	1.3	8
554	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 423-433	1.9	4
553	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 597-602	4.5	15
552	Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E35-E37	7.1	12
551	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-B pathways. <i>Leukemia</i> , <b>2018</b> , 32, 654-662	10.7	18
550	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. <i>Leukemia</i> , <b>2018</b> , 32, 543-546	10.7	2
549	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , <b>2018</b> , 101, 703	3.8	5
548	Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E243-E246	7.1	27
547	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E216-E219	7.1	9
546	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , <b>2018</b> , 36, 757-764	1.3	3
545	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1402-1410	7.1	19
544	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1767-1774	3	9
543	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , <b>2018</b> , 132, 5565-5565	2.2	3

542	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , <b>2018</b> , 132, 3012-3012	2.2	1
541	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. <i>Blood</i> , <b>2018</b> , 132, 46-46	2.2	3
540	Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients. <i>Blood</i> , <b>2018</b> , 132, 1607-1607	2.2	1
539	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , <b>2018</b> , 132, 393-393	2.2	1
538	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 4412-4412	2.2	2
537	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , <b>2018</b> , 132, 1834-1834	2.2	1
536	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 585-585	2.2	4
535	NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1832-1832	2.2	1
534	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , <b>2018</b> , 132, 43-43	2.2	6
533	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , <b>2018</b> , 132, 2962-2962	2.2	1
532	Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome. <i>Blood</i> , <b>2018</b> , 132, 1829-1829	2.2	
531	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study. <i>Blood</i> , <b>2018</b> , 132, 3147-3147	2.2	1
530	The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Blood</i> , <b>2018</b> , 132, 2890-2890	2.2	
529	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , <b>2018</b> , 132, 2861-2861	2.2	
528	Eltrombopag for the Treatment of Aplastic Anemia in Europe. <i>Blood</i> , <b>2018</b> , 132, 1304-1304	2.2	
527	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2838-2838	2.2	
526	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , <b>2018</b> , 124, 1251-1259	6.4	21
525	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 689-696	2.2	81

524	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2845-2853	2.2	164
523	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 108	7	22
522	Mutant p53 blocks SESN1/AMPK/PGC-1 $\alpha$ /UCP2 axis increasing mitochondrial O <sub>2</sub> production in cancer cells. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 994-1008	8.7	22
521	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 63	7	9
520	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, e401-e419	2	37
519	FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 372-381	1.9	10
518	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. <i>Leukemia</i> , <b>2017</b> , 31, 115-122	10.7	49
517	Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 163-164	21.7	
516	Diffuse large B-cell lymphoma genotyping on the liquid biopsy. <i>Blood</i> , <b>2017</b> , 129, 1947-1957	2.2	113
515	Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice. <i>Cancer Research</i> , <b>2017</b> , 77, 1250-1260	10.1	45
514	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology, the</i> , <b>2017</b> , 4, e15-e23	14.6	75
513	Mutations in the 3' untranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2017</b> , 102, e305-e309	6.6	11
512	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5292-5301	12.9	20
511	Common nonmutational activation in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E2911-E2919	11.5	83
510	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2501-2504	1.9	16
509	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. <i>Leukemia</i> , <b>2017</b> , 31, 2407-2415	10.7	36
508	Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. <i>Leukemia</i> , <b>2017</b> , 31, 1882-1893	10.7	39
507	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. <i>Leukemia</i> , <b>2017</b> , 31, 1368-1374	10.7	41

506	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of gene refines prognosis in treatment-naïve chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2017</b> , 102, e144-e147	6.6	4
505	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1591-1597	2.2	55
504	A MALT lymphoma prognostic index. <i>Blood</i> , <b>2017</b> , 130, 1409-1417	2.2	96
503	Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?. <i>Blood</i> , <b>2017</b> , 130, 859-866	2.2	39
502	Mutational status of is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2017</b> , 102, e443-e446	6.6	8
501	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1076-1088	21.7	72
500	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 258-267	4.5	6
499	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 1547-1554	10.7	34
498	The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. <i>Hematology American Society of Hematology Education Program</i> , <b>2017</b> , 2017, 329-337	3.1	39
497	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 90013-90027	3.3	5
496	Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7538-7538	2.2	
495	Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7507-7507	2.2	3
494	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. <i>Blood Advances</i> , <b>2016</b> , 1, 47-61	7.8	33
493	11. Chronic lymphocytic leukemia <b>2016</b> , 205-228		
492	Regulatory agencies should engage in drug pricing. <i>BMJ</i> , <b>2016</b> , 354, i4524	5.9	0
491	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2016</b> , 101, 77-85	6.6	37
490	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1362-73	2.2	88
489	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 995-1001	7.1	30

488	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e493	7	55
487	Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e425	7	9
486	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 400-410	1.0	3
485	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , <b>2016</b> , 17, 27-38	21.7	576
484	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1376-85	2.2	101
483	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 972-9	2.2	228
482	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 496-508	21.7	112
481	Richter syndrome: pathogenesis and management. <i>Seminars in Oncology</i> , <b>2016</b> , 43, 311-9	5.5	52
480	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , <b>2016</b> , 30, 182-9	10.7	59
479	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 181-94	15.9	33
478	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. <i>Blood</i> , <b>2016</b> , 128, 1214-1214	2.2	5
477	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , <b>2016</b> , 128, 4376-4376	2.2	1
476	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. <i>Blood</i> , <b>2016</b> , 128, 623-623	2.2	7
475	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , <b>2016</b> , 16, 659-668	2.8	9
474	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7545-7545	2.2	
473	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 4367-4367	2.2	
472	A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. <i>European Journal of Haematology</i> , <b>2016</b> , 96, 352-9	3.8	20
471	An anomalous case of acute coronary syndrome: the unexpected autoimmune duo. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 2, e118-e121	1.9	0

470	Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 371-383	4.5	15
469	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , <b>2016</b> , 128, 2093-2095	2.2	42
468	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , <b>2016</b> , 101, 959-67	6.6	41
467	The clinical implications of gene mutations in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 849-54	8.7	25
466	Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2016</b> , 101, e135-8	6.6	30
465	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. <i>Lancet Haematology</i> , <b>2016</b> , 3, e128-38	14.6	28
464	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2016</b> , 30, 2011-2018	10.7	33
463	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , <b>2016</b> , 30, 2032-2038	10.7	55
462	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , <b>2016</b> , 46, 18-25	2.7	9
461	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , <b>2016</b> , 127, 1007-16	2.2	110
460	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <i>Haematologica</i> , <b>2016</b> , 101, 1002-9	6.6	30
459	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , <b>2016</b> , 101, 941-50	6.6	30
458	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1025-1036	21.7	113
457	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 744	24.3	2
456	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , <b>2015</b> , 100, 517-24	6.6	4
455	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 1001-9	3.8	26
454	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 516-32	24.3	283
453	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3150-8	1.9	17

452	Histologic transformation in marginal zone lymphomas □ <i>Annals of Oncology</i> , <b>2015</b> , 26, 2329-35	10.3	61
451	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , <b>2015</b> , 20, 1149-53 <sup>57</sup>	5.7	37
450	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1506-1514 <sup>60</sup>	21.7	60
449	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3467-74	2.2	129
448	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , <b>2015</b> , 39, 1055-9	2.7	43
447	Life expectancy of young adults with follicular lymphoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2317-22	10.3	27
446	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. <i>Haematologica</i> , <b>2015</b> , 100, 246-52	6.6	51
445	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2015</b> , 39, 859-65	2.7	12
444	The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , <b>2015</b> , 29, 503-7	10.7	62
443	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 282-8	4.4	108
442	Recurrent mutations refine prognosis in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2015</b> , 29, 329-36	10.7	220
441	BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. <i>Hematological Oncology</i> , <b>2015</b> , 33, 23-30	1.3	15
440	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 361-70	4.5	40
439	II. Challenges in the management of post-transplant lymphoproliferative disorder. <i>Hematological Oncology</i> , <b>2015</b> , 33 Suppl 1, 96-9	1.3	4
438	Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A. <i>Haematologica</i> , <b>2015</b> , 100, 881-92	6.6	29
437	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 125, 111-23	2.2	117
436	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , <b>2015</b> , 125, 1922-31	2.2	40
435	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , <b>2015</b> , 125, 3580-7	2.2	40

434	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 126, 1921-4	2.2	167
433	Prognostic relevance of MYD88 mutations in CLL: the jury is still out. <i>Blood</i> , <b>2015</b> , 126, 1043-4	2.2	29
432	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , <b>2015</b> , 100, e501-4	6.6	18
431	PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. <i>Hematological Oncology</i> , <b>2015</b> , 33, 125-32	1.3	14
430	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 970-4	7.1	2
429	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 2687-94	4.4	3
428	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2637-42	1.9	41
427	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2425-37	59.2	950
426	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. <i>Leukemia Research</i> , <b>2015</b> , 39, 296-306	2.7	37
425	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E80-5	7.1	59
424	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , <b>2015</b> , 29, 1360-5	10.7	41
423	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. <i>Blood</i> , <b>2015</b> , 126, 1669-1669	2.2	14
422	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , <b>2015</b> , 126, 495-495	2.2	2
421	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , <b>2015</b> , 6, 19102-17	3.3	13
420	Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. <i>Oncotarget</i> , <b>2015</b> , 6, 18653-63	3.3	16
419	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , <b>2015</b> , 126, 2099-2099	2.2	
418	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , <b>2015</b> , 126, 2925-2925	2.2	
417	Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment. <i>Blood</i> , <b>2015</b> , 126, 4145-4145	2.2	1



416	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. <i>Blood</i> , <b>2015</b> , 126, 5263-5263	2.2	
415	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 69-76	4.5	32
414	Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2014</b> , 28, 1060-70	10.7	83
413	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 629-39	4.5	44
412	Globalisation of clinical trials and ethics of benefit sharing. <i>Lancet Haematology,the</i> , <b>2014</b> , 1, e54-6	14.6	4
411	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 896-9	4.5	
410	Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 224-32	4.5	22
409	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 634-40	2.2	171
408	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , <b>2014</b> , 93, 1765-74	3	29
407	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. <i>Blood</i> , <b>2014</b> , 123, 2378-88	2.2	64
406	CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 897-904	2.2	118
405	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 730-7	21.7	135
404	Genetics of follicular lymphoma transformation. <i>Cell Reports</i> , <b>2014</b> , 6, 130-40	10.6	371
403	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , <b>2014</b> , 42, 126-36.e1	3.1	20
402	NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2785-92	1.9	40
401	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , <b>2014</b> , 99, 1285-91	6.6	1
400	Lymphocytosis and ibrutinib treatment of CLL. <i>Blood</i> , <b>2014</b> , 123, 1772-4	2.2	18
399	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. <i>Blood</i> , <b>2014</b> , 124, 2930-6	2.2	176

398	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. <i>Haematologica</i> , <b>2014</b> , 99, 1611-7	6.6	16
397	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. <i>Haematologica</i> , <b>2014</b> , 99, 888-96	6.6	38
396	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , <b>2014</b> , 99, e159-61	6.6	4
395	Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. <i>PLoS ONE</i> , <b>2014</b> , 9, e98818	3.7	28
394	Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 718-20	4.5	19
393	Analysis of human papillomavirus and Merkel cell polyomavirus infection in skin lesions and eyebrow hair bulbs from a cohort of patients with chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 1525-8	4	12
392	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells. <i>Leukemia</i> , <b>2014</b> , 28, 705-8	10.7	5
391	MYC network mutations in high-risk chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , <b>2014</b> , 32, 155-7	1.3	1
390	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 1266-73	15.4	62
389	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 166-77	4.5	23
388	Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. <i>Hematological Oncology</i> , <b>2014</b> , 32, 133-8	1.3	10
387	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. <i>Cancer</i> , <b>2014</b> , 120, 1838-46	6.4	107
386	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6398-405	12.9	69
385	Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. <i>Blood</i> , <b>2014</b> , 124, 3831-3	2.2	22
384	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , <b>2014</b> , 25, 447-54	10.3	31
383	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 74-82	7.1	18
382	Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. <i>Seminars in Hematology</i> , <b>2014</b> , 51, 168-76	4	27
381	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , <b>2014</b> , 93, 221-231	3	27

380	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 2139-2147	2.47	247
379	Genetic Mechanisms of Immune Escape in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 1692-1692	2.2	2
378	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , <b>2014</b> , 3,	8.9	37
377	Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 295-295	2.2	1
376	Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>2013</b> , 31, 22-8	1.3	13
375	Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis. <i>Hematological Oncology</i> , <b>2013</b> , 31, 54-54	1.3	24
374	Risk factors of central nervous system relapse in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1908-14	1.9	27
373	Molecular bases of chronic lymphocytic leukemia in light of new treatments. <i>Immunology Letters</i> , <b>2013</b> , 155, 51-5	4.1	10
372	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1378-84	10.3	13
371	Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 194-204	4.5	16
370	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1786-7	1.9	7
369	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , <b>2013</b> , 5, 826-37	6.6	83
368	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , <b>2013</b> , 122, 2673-82	2.2	154
367	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 1403-12	2.2	357
366	Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 415-8	4.5	12
365	Genome-wide DNA profiling of HIV-related B-cell lymphomas. <i>Methods in Molecular Biology</i> , <b>2013</b> , 973, 213-26	1.4	
364	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 2485-9	1.9	20
363	Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. <i>Seminars in Cancer Biology</i> , <b>2013</b> , 23, 422-30	12.7	42

362	rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 221-8	4.5	1
361	Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5890-900	12.9	50
360	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1506-13	2.2	193
359	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , <b>2013</b> , 6, 83	22.4	14
358	Clinical implications of the molecular genetics of chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2013</b> , 98, 675-85	6.6	58
357	MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1087-90	1.9	57
356	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 658-61	1.9	45
355	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2108-12	10.3	104
354	Richter syndrome. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> , 792, 173-91	3.6	23
353	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 53-7	1.9	36
352	ARHGDI1, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 596-9	4.5	3
351	Genome-wide high resolution DNA profiling of hairy cell leukaemia. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 566-9	4.5	17
350	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 465-73	4.5	36
349	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2013</b> , 98, 953-63	6.6	148
348	Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. <i>Leukemia</i> , <b>2013</b> , 27, 695-701	10.7	27
347	CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. <i>Leukemia</i> , <b>2013</b> , 27, 1177-81	10.7	11
346	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , <b>2013</b> , 122, 2233-41	2.2	33
345	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 4902-5	2.2	94

344	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , <b>2013</b> , 122, 3317-21	2.2	36
343	Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , <b>2013</b> , 31, 88-95 <sup>1-3</sup>		20
342	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , <b>2013</b> , 98, 1732-8	6.6	48
341	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , <b>2013</b> , 122, 3047-3047	2.2	2
340	Differential Distribution Of Recurrent Gene Mutations In Subsets Of Chronic Lymphocytic Leukemia Patients With Stereotyped B-Cell Receptors: Results From A Multicenter Project Of The European Research Initiative On CLL In A Series Of 2482 Cases. <i>Blood</i> , <b>2013</b> , 122, 4113-4113	2.2	1
339	Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. <i>Blood</i> , <b>2013</b> , 122, 1614-1614	2.2	
338	Absence of NOTCH1 gene mutations in MALT lymphomas. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 382-4	4.5	9
337	Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 426-9	4.5	70
336	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 18	8.5	18
335	Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. <i>Cancer</i> , <b>2012</b> , 118, 1014-22	6.4	96
334	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. <i>Haematologica</i> , <b>2012</b> , 97, 437-41	6.6	151
333	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. <i>Blood</i> , <b>2012</b> , 119, 2106-9	2.2	8
332	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 2854-62	2.2	236
331	Molecular pathogenesis of chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3432-8	15.9	124
330	Molecular genetics of high-risk chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , <b>2012</b> , 5, 593-602		13
329	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , <b>2012</b> , 5, 44	22.4	37
328	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1537-51	16.6	289
327	The miR-17~92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. <i>Leukemia</i> , <b>2012</b> , 26, 1584-93	10.7	64

326	Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 235-8	3.3	4
325	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. <i>Mechanisms of Ageing and Development</i> , <b>2012</b> , 133, 479-88	5.6	9
324	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , <b>2012</b> , 97, 849-53	6.6	9
323	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). <i>Annals of Hematology</i> , <b>2012</b> , 91, 1013-22	3	33
322	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 521-9	2.2	337
321	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , <b>2012</b> , 30, 46-9	1.3	18
320	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 3006-10	7.5	24
319	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 354-7	4.5	9
318	The spectrum of genetic defects in chronic lymphocytic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2012</b> , 4, e2012076	3.2	9
317	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 71-6	1.9	9
316	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , <b>2012</b> , 26, 1301-12	10.7	63
315	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , <b>2012</b> , 23, 729-735	10.3	17
314	Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 3323-34	3.3	11
313	Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. <i>Haematologica</i> , <b>2012</b> , 97, 153-4	6.6	34
312	Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab. <i>Blood</i> , <b>2012</b> , 120, 1637-1637	2.2	4
311	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. <i>Blood</i> , <b>2012</b> , 120, 1784-1784	2.2	2
310	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. <i>Blood</i> , <b>2012</b> , 120, 929-929	2.2	1
309	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , <b>2012</b> , 120, 2870-2870		

308	Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Preliminary Results of the Unit Study.. <i>Blood</i> , <b>2012</b> , 120, 2192-2192	2.2	
307	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>2012</b> , 120, 1772-1772	2.2	
306	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , <b>2012</b> , 120, 3653-3653	2.2	
305	Analysis of the coding genome of diffuse large B-cell lymphoma. <i>Nature Genetics</i> , <b>2011</b> , 43, 830-7	36.3	760
304	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1389-401	16.6	483
303	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , <b>2011</b> , 118, 6904-8	2.2	298
302	Inactivating mutations of acetyltransferase genes in B-cell lymphoma. <i>Nature</i> , <b>2011</b> , 471, 189-95	50.4	684
301	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2011</b> , 117, 2405-13	2.2	28
300	Alteration of BIRC3 and multiple other NF- $\kappa$ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , <b>2011</b> , 118, 4930-4	2.2	151
299	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , <b>2011</b> , 117, 1595-604	2.2	145
298	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. <i>Blood</i> , <b>2011</b> , 118, 6141-52	2.2	103
297	Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. <i>BMJ Case Reports</i> , <b>2011</b> , 2011,	0.9	12
296	Genomic profiles of MALT lymphomas: variability across anatomical sites. <i>Haematologica</i> , <b>2011</b> , 96, 1064-666		36
295	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 3-14	4.5	21
294	A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 284-94	4.5	22
293	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 499-503	4.5	11
292	Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , <b>2011</b> , 155, 274-7	4.5	42
291	Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 229-33	4.5	17

290	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 590-9	4.5	35
289	E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2011</b> , 25, 479-88	10.7	27
288	A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. <i>Leukemia</i> , <b>2011</b> , 25, 1268-77	10.7	39
287	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , <b>2011</b> , 87, 409-18	3.8	12
286	Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. <i>Leukemia Research</i> , <b>2011</b> , 35, 1419-22	2.7	4
285	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. <i>Advances in Therapy</i> , <b>2011</b> , 28, 684-97	4.1	14
284	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 993-7	7.1	4
283	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 1007-12	7.1	37
282	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 633-43	5	57
281	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , <b>2011</b> , 29, 38-41	1.3	23
280	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , <b>2011</b> , 29, 91-9	1.3	24
279	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. <i>Hematological Oncology</i> , <b>2011</b> , 29, 164-6	1.3	3
278	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 823-32	1.9	20
277	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , <b>2011</b> , 117, 3391-401	2.2	249
276	Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 79, 31-42	7	28
275	Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. <i>Cancer Research</i> , <b>2011</b> , 71, 4473-83	10.1	131
274	Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. <i>Haematologica</i> , <b>2011</b> , 96, 1496-503	6.6	13
273	Predictive markers and driving factors behind Richter syndrome development. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 433-42	3.5	12



272	Tracking the biological risk of coronary artery disease in HIV-infected individuals: the case of circulating endothelial progenitor cells. <i>Aids</i> , <b>2011</b> , 25, 379-81	3.5	1
271	CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>2011</b> , 118, 621-621	2.2	
270	Alteration of BIRC3 and Multiple Other NF- $\kappa$ B Pathway Genes in Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 264-264	2.2	
269	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , <b>2011</b> , 118, 263-263		
268	Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 245-55	4.5	56
267	IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 299-302	4.5	1
266	Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). <i>British Journal of Haematology</i> , <b>2010</b> , 149, 376-82	4.5	44
265	Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 569-77	4.5	45
264	Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)/CD49d(+) chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 111-3	4.5	24
263	Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 229-32	4.5	2
262	MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 wild-type CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 237-9	4.5	22
261	BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 702-4	4.5	3
260	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 221-31	4.5	45
259	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 435-9	4.5	15
258	CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. <i>Leukemia</i> , <b>2010</b> , 24, 958-69	10.7	72
257	Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 620-8	12.9	38
256	Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1189-1195	10.3	39
255	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , <b>2010</b> , 95, 1144-9	6.6	37

254	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , <b>2010</b> , 8, 23	8.5	15
253	Free light-chains and renal disorders: when small is worse. <i>Lancet, The</i> , <b>2010</b> , 376, 1221; author reply 1221-2	4.0	
252	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , <b>2010</b> , 95, 1792-6	6.6	74
251	Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 115, 1106-7	2.2	5
250	Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. <i>Blood</i> , <b>2010</b> , 116, 5957-60	2.2	39
249	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , <b>2010</b> , 116, 4745-53	2.2	325
248	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 822-38	1.9	8
247	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 116, 584-92	2.2	46
246	Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , <b>2010</b> , 196, 89-92		1
245	Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. <i>Cancer</i> , <b>2010</b> , 116, 1485-94	6.4	85
244	Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. <i>Cancer</i> , <b>2010</b> , 116, 2188-200	6.4	24
243	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , <b>2010</b> , 28, 62-7	1.3	34
242	Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 461-2	7.1	3
241	Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 541-4	7.1	10
240	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 619-22	7.1	9
239	Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , <b>2010</b> , 34, e243-5	2.7	2
238	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , <b>2010</b> , 116, 1371-1371	2.2	1
237	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Blood</i> , <b>2010</b> , 116, 1940-1940	2.2	3

236	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , <b>2010</b> , 116, 3611-3611	2.2	1
235	Genesis and consequences of genetic lesions in lymphoid neoplasms <b>2010</b> , 361-379		
234	Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study. <i>Blood</i> , <b>2010</b> , 116, 4953-4953	2.2	
233	CD38 Expression Marks CLL Cells with Invasive Properties. <i>Blood</i> , <b>2010</b> , 116, 2422-2422	2.2	
232	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. <i>Blood</i> , <b>2010</b> , 116, 3375-3375 <sup>2.2</sup>		
231	Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4439-45	12.9	12
230	The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 995-1004	12.9	245
229	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4415-22	12.9	155
228	CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. <i>Cancer Research</i> , <b>2009</b> , 69, 4001-9	10.1	134
227	Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 697-8	7.1	2
226	Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands. <i>Head and Neck</i> , <b>2009</b> , 31, 1181-7	4.2	13
225	Richter syndrome: molecular insights and clinical perspectives. <i>Hematological Oncology</i> , <b>2009</b> , 27, 1-10	1.3	95
224	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 2360-6	7.5	15
223	Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. <i>Journal of Pathology</i> , <b>2009</b> , 218, 478-86	9.4	34
222	14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 131-3	4.5	11
221	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 492-506	4.5	100
220	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 64-75	4.5	120
219	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , <b>2009</b> , 23, 1118-26	10.7	87

218	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2009</b> , 23, 1062-72	10.7	85
217	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , <b>2009</b> , 7, 76	8.5	31
216	Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 604-11	1.9	26
215	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , <b>2009</b> , 94, 1250-8	6.6	56
214	The NF- $\kappa$ B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. <i>Blood</i> , <b>2009</b> , 113, 4918-21	2.2	205
213	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. <i>Genome Research</i> , <b>2009</b> , 19, 438-51	9.7	201
212	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , <b>2009</b> , 114, 860-860	2.2	1
211	Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2009</b> , 1, e2009018	3.2	12
210	Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 1260-1260	2.2	
209	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. <i>Blood</i> , <b>2009</b> , 114, 4374-4374	2.2	
208	CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4.. <i>Blood</i> , <b>2009</b> , 114, 2328-2328	2.2	
207	Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.. <i>Blood</i> , <b>2009</b> , 114, 672-672		
206	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , <b>2008</b> , 22, 224-6	10.7	7
205	Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 734-6	4.5	12
204	Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 504-11	4.5	51
203	High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 622-30	4.5	31
202	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , <b>2008</b> , 142, 202-15	4.5	173
201	Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 532-6	4.5	53

200	CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. <i>Future Oncology</i> , <b>2008</b> , 4, 355-8	3.6	7
199	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 1575-9	6.6	66
198	Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 111, 466-8	2.2	13
197	CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?. <i>Blood</i> , <b>2008</b> , 111, 5646-53	2.2	63
196	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 697-705	6.6	30
195	Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. <i>Haematologica</i> , <b>2008</b> , 93, 1178-85	6.6	23
194	KSHV/HHV8 Doesn't Play a Significant Role in the Development of Plasmablastic Lymphoma of the Oral Cavity. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 172-174	6.7	9
193	Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: resolution with rituximab. <i>Leukemia Research</i> , <b>2008</b> , 32, 829-34	2.7	5
192	Human CD38 Is a Potential Therapeutic Target for Selected Chronic Lymphocytic Leukemia cases.. <i>Blood</i> , <b>2008</b> , 112, 2096-2096	2.2	
191	Transient monoclonal expansion of CD8+/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection. <i>American Journal of Hematology</i> , <b>2007</b> , 82, 1103-5	7.1	28
190	Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. <i>Leukemia Research</i> , <b>2007</b> , 31, 97-101	2.7	8
189	Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribine treatment. <i>Leukemia Research</i> , <b>2007</b> , 31, 873-6	2.7	5
188	Simultaneous diagnosis of CD3+ T-cell large granular lymphocyte leukaemia and true thymic hyperplasia. <i>Leukemia Research</i> , <b>2007</b> , 31, 1019-21	2.7	3
187	Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 249-52	4.5	19
186	JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 813-4	4.5	20
185	Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. <i>Journal of Infection</i> , <b>2007</b> , 54, 298-306	18.9	16
184	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , <b>2007</b> , 109, 2989-98	2.2	57
183	CD40 promotes lymphoma from nuclear hideaway. <i>Blood</i> , <b>2007</b> , 110, 1710-1711	2.2	

182	Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 158-67	1.9	16
181	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , <b>2007</b> , 110, 3089-3089	2.2	
180	Genome Wide-DNA Profiling of HIV-Related Non-Hodgkin Lymphomas: Implications for Disease Pathogenesis and Histogenesis.. <i>Blood</i> , <b>2007</b> , 110, 561-561	2.2	
179	Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. <i>Hematological Oncology</i> , <b>2006</b> , 24, 212-9	1.3	14
178	Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-associated polyclonal body cavity effusions that mimic primary effusion lymphomas. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 1746-8; author reply 1749-50	7.5	9
177	Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. <i>Molecular Medicine</i> , <b>2006</b> , 12, 300-8	6.2	18
176	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. <i>Blood</i> , <b>2006</b> , 108, 1013-20	2.2	59
175	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , <b>2006</b> , 107, 4643-9	2.2	177
174	B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution. <i>Transplantation</i> , <b>2006</b> , 82, 1013-23	1.8	13
173	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 303-16	4.5	152
172	Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 27-36	4.5	52
171	JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , <b>2006</b> , 135, 267-8	4.5	29
170	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). <i>Leukemia Research</i> , <b>2006</b> , 30, 1197-9	2.7	15
169	Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2006</b> , 91, 1405-9	6.6	57
168	Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. <i>Journal of Molecular Diagnostics</i> , <b>2005</b> , 7, 17-27	5.1	126
167	Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. <i>British Journal of Haematology</i> , <b>2005</b> , 130, 92-5	4.5	10
166	Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. <i>Leukemia</i> , <b>2005</b> , 19, 2363-7	3.6	26
165	Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. <i>Hematological Oncology</i> , <b>2005</b> , 23, 61-7	1.3	113

164	Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. <i>Journal of Pathology</i> , <b>2005</b> , 206, 87-91	9.4	26
163	KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. <i>Journal of Clinical Pathology</i> , <b>2005</b> , 58, 1039-45	3.9	43
162	Molecular Analysis of Immunoglobulin Variable Genes in HIV-Related Non-Hodgkin Lymphoma: Implications for Disease Pathogenesis and Histogenesis.. <i>Blood</i> , <b>2005</b> , 106, 330-330	2.2	
161	Molecular Analysis of Posttransplant Lymphoproliferative Disorders (PTLD) of Donor Origin Occuring in Liver Transplant Patients.. <i>Blood</i> , <b>2005</b> , 106, 1916-1916	2.2	
160	Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 357-62	1.9	12
159	The mutator pathway is a feature of immunodeficiency-related lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 5002-7	11.5	61
158	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. <i>British Journal of Haematology</i> , <b>2004</b> , 124, 604-9	4.5	5
157	Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 657-64	4.5	66
156	Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 362-4	4.5	21
155	Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2004</b> , 18, 1941-7	10.7	34
154	Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 41, 321-9	5	7
153	Is Plasmablastic Lymphoma of the Oral Cavity an HHV-8-associated Disease?. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 1538-1540	6.7	31
152	Immunoglobulin (Ig) Variable Gene Usage Identifies a Subset of Unmutated Chronic Lymphocytic Leukemia (CLL) Patients Expressing 51p1-Like alleles and a Particularly Unfavorable Prognostic Outcome.. <i>Blood</i> , <b>2004</b> , 104, 1922-1922	2.2	
151	Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. <i>Haematologica</i> , <b>2004</b> , 89, 154-64	6.6	69
150	Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. <i>Haematologica</i> , <b>2004</b> , 89, 759-61	6.6	25
149	Is plasmablastic lymphoma of the oral cavity an HHV-8-associated disease?. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 1251-2	6.7	3
148	Pathobiology of primary mediastinal B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44 Suppl 3, S21-6	1.9	48
147	Are Gilbert's syndrome and liver involvement genetically linked in infectious mononucleosis?. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, 1110-1	3.4	6

146	Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. <i>Blood</i> , <b>2003</b> , 101, 4115-21	2.2	219
145	Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. <i>Blood</i> , <b>2003</b> , 102, 1833-41	2.2	124
144	Molecular histogenesis of posttransplantation lymphoproliferative disorders. <i>Blood</i> , <b>2003</b> , 102, 3775-85	2.2	97
143	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , <b>2003</b> , 107, 958-61	7.5	8
142	Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture. <i>Journal of Cellular Biochemistry</i> , <b>2003</b> , 88, 569-77	4.7	20
141	Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 475-8	4.5	40
140	A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. <i>Leukemia</i> , <b>2003</b> , 17, 554-9	10.7	8
139	The human marginal zone B cell. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 987, 117-24	6.5	31
138	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. <i>American Journal of Pathology</i> , <b>2003</b> , 162, 243-53	5.8	137
137	Simian virus 40 infection in lymphoproliferative disorders. <i>Lancet, The</i> , <b>2003</b> , 361, 1565; author reply 1565-6	40	2
136	Simian virus 40 infection in lymphoproliferative disorders. <i>Lancet, The</i> , <b>2003</b> , 361, 88-9	40	49
135	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , <b>2003</b> , 102, 1035-41	2.2	70
134	Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. <i>International Journal of Biological Markers</i> , <b>2003</b> , 18, 218-21	2.8	16
133	Messengers of cell death: apoptotic signaling in health and disease. <i>Haematologica</i> , <b>2003</b> , 88, 212-8	6.6	94
132	Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. <i>British Journal of Haematology</i> , <b>2002</b> , 117, 366-72	4.5	84
131	Molecular histogenesis of plasmablastic lymphoma of the oral cavity. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 622-8	4.5	69
130	Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 923-9	4.5	29
129	Simian AIDS-related lymphoma growth in severe combined immunodeficiency mice is independent of karyotypic abnormalities or Bcl-6 mutations. <i>AIDS Research and Human Retroviruses</i> , <b>2002</b> , 18, 383-90	1.6	3



128	Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. <i>Journal of Clinical Pathology</i> , <b>2002</b> , 55, 684-8	3.9	45
127	Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. <i>Hematology</i> , <b>2002</b> , 7, 239-52	2.2	27
126	Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. <i>Leukemia</i> , <b>2002</b> , 16, 268-75	10.7	33
125	Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 26-32	9.7	219
124	Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 163-71	5.8	10
123	Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma. <i>AIDS Research and Human Retroviruses</i> , <b>2002</b> , 18, 19-26	1.6	14
122	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. <i>FEBS Letters</i> , <b>2002</b> , 518, 119-23	3.8	10
121	Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. <i>Human Pathology</i> , <b>2002</b> , 33, 937-43	3.7	46
120	Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. <i>Cancer Research</i> , <b>2002</b> , 62, 4089-94	10.1	41
119	Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. <i>Blood</i> , <b>2001</b> , 97, 744-51	2.2	214
118	Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. <i>Blood</i> , <b>2001</b> , 97, 2098-104	2.2	165
117	Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. <i>Advances in Cancer Research</i> , <b>2001</b> , 80, 115-46	5.9	60
116	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , <b>2001</b> , 193, 200-9	9.4	41
115	Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. <i>Leukemia</i> , <b>2001</b> , 15, 186-7	10.7	17
114	Acquired immunodeficiency syndrome-related cancer. A study model for the mechanisms contributing to the genesis of cancer. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 1184-7	7.5	13
113	Genetic pathways and histogenetic models of AIDS-related lymphomas. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 1270-5	7.5	27
112	Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. <i>International Journal of Cancer</i> , <b>2000</b> , 85, 124-30	7.5	23
111	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 27, 177-82	5	9

110	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , <b>2000</b> , 14, 271-7	10.7	53
109	The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. <i>Leukemia</i> , <b>2000</b> , 14, 285-91	10.7	31
108	Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. <i>Leukemia</i> , <b>2000</b> , 14, 811-5	10.7	42
107	Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 247-257	4.5	1
106	Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3325-30	2.2	84
105	Primary effusion lymphoma cell lines harbouring human herpesvirus type-8. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 36, 447-56	1.9	27
104	An apparent interlocus gene conversion-like event at a putative tumor suppressor gene locus on human chromosome 6q27 in a Burkitt's lymphoma cell line. <i>DNA Research</i> , <b>2000</b> , 7, 261-72	4.5	6
103	Burkitt's lymphoma: historical background and recent insights into classification and pathogenesis. <i>Annals of Otology, Rhinology and Laryngology</i> , <b>2000</b> , 109, 693-702	2.1	16
102	Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27(kip1). <i>American Journal of Pathology</i> , <b>2000</b> , 156, 1209-15	5.8	27
101	Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: pathogenetic and histogenetic implications. <i>Human Pathology</i> , <b>2000</b> , 31, 871-3	3.7	20
100	Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. <i>Journal of Clinical Virology</i> , <b>2000</b> , 16, 215-24	14.5	23
99	The role of cytokines in the pathogenesis and management of AIDS-related lymphomas. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 38, 481-8	1.9	18
98	Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. <i>Current Topics in Microbiology and Immunology</i> , <b>2000</b> , 252, 275-84	3.3	8
97	Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 247-57	4.5	53
96	HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. <i>Brain Pathology</i> , <b>1999</b> , 9, 199-208	6	21
95	Expression of BCL-6 Protein and Cd138/Syndecan-1 as B-Cell Markers in Hodgkin'S Disease. <i>International Journal of Biological Markers</i> , <b>1999</b> , 14, 144-148	2.8	2
94	AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. <i>Annals of Otology, Rhinology and Laryngology</i> , <b>1999</b> , 108, 95-9	2.1	67
93	Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. <i>Leukemia</i> , <b>1999</b> , 13, 634-40	10.7	65

92	Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. <i>Leukemia</i> , <b>1999</b> , 13, 1093-9	10.7	65
91	Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions. <i>Medical Oncology</i> , <b>1999</b> , 16, 8-12	3.7	13
90	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Annals of Neurology</i> , <b>1999</b> , 45, 259-261	9.4	34
89	Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. <i>Genes Chromosomes and Cancer</i> , <b>1999</b> , 24, 16-23	5	81
88	Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 2863-74	6.1	21
87	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma <b>1999</b> , 45, 259		1
86	The Pathologic Spectrum of Aids- Related Non-Hodgkin's Lymphomas <b>1999</b> , 191-202		2
85	Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). <i>Leukemia</i> , <b>1998</b> , 12, 1507-17	10.7	112
84	A role for growth hormone and prolactin in leukaemia and lymphoma?. <i>Cellular and Molecular Life Sciences</i> , <b>1998</b> , 54, 1095-101	10.3	21
83	Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. <i>British Journal of Haematology</i> , <b>1998</b> , 102, 1081-9	4.5	71
82	Patterns of cytokine expression in AIDS-related non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 143-9	4.5	21
81	Cloning and mapping of human chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma and multiple tumor types. <i>Genomics</i> , <b>1998</b> , 50, 170-86	4.3	30
80	BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 31, 39-46	1.9	12
79	p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR). <i>Leukemia and Lymphoma</i> , <b>1998</b> , 29, 595-605	1.9	14
78	Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. <i>Journal of the National Cancer Institute Monographs</i> , <b>1998</b> , 95-100	4.8	39
77	Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. <i>Annals of Oncology</i> , <b>1998</b> , 9, 55-61	10.3	77
76	Involvement of the bcl-6 gene in AIDS-related lymphomas. <i>Annals of Oncology</i> , <b>1997</b> , 8, S105-S108	10.3	6
75	Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 1193-7	7	23

74	HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. <i>Radiology</i> , <b>1997</b> , 205, 459-63	20.5	68
73	Molecular pathways in low grade B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 26 Suppl 1, 107-13	1.9	10
72	Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma. <i>Annals of Oncology</i> , <b>1997</b> , 8, 987-94	10.3	29
71	Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 24, 257-66	1.9	32
70	Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. <i>Genomics</i> , <b>1997</b> , 42, 369-77	4.3	107
69	Pathological and immunophenotypic features of adult non-Hodgkin's lymphomas by age group. <i>Human Pathology</i> , <b>1997</b> , 28, 580-7	3.7	11
68	Microsatellite instability in KSHV/HHV-8 positive body-cavity-based lymphoma. <i>Human Pathology</i> , <b>1997</b> , 28, 748-50	3.7	17
67	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , <b>1997</b> , 89, 3787-3794	2.2	51
66	AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation. <i>Blood</i> , <b>1997</b> , 90, 1337-1337	2.2	39
65	BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas. <i>Blood</i> , <b>1997</b> , 90, 2445-2450	2.2	42
64	HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. <i>British Journal of Haematology</i> , <b>1997</b> , 97, 515-22	4.5	103
63	Genetic heterogeneity of AIDS-related small non-cleaved cell lymphoma. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 726-32	4.5	12
62	Point mutations of the BCL-6 gene in Burkitt's lymphoma. <i>British Journal of Haematology</i> , <b>1997</b> , 99, 168-70	4.5	31
61	Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. <i>British Journal of Haematology</i> , <b>1997</b> , 96, 308-13	4.5	9
60	Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. <i>American Journal of Hematology</i> , <b>1997</b> , 56, 206-13	7.1	29
59	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 19, 250-255	5	13
58	Establishment of HHV-8-positive and HHV-8-negative lymphoma cell lines from primary lymphomatous effusions. <i>International Journal of Cancer</i> , <b>1997</b> , 73, 562-9	7.5	53
57	High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. <i>Cytometry</i> , <b>1997</b> , 30, 33-38		11

56	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , <b>1997</b> , 89, 3787-3794	2.2	1
55	BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas. <i>Blood</i> , <b>1997</b> , 90, 2445-2450	2.2	3
54	AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation. <i>Blood</i> , <b>1997</b> , 90, 1337-1337	2.2	2
53	Morphologic patterns and molecular pathways of AIDS-related head and neck and other systemic lymphomas. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , <b>1996</b> , 105, 495-9	2.1	2
52	Herpesvirus-like DNA sequences selectively cluster with body cavity-based lymphomas throughout the spectrum of AIDS-related lymphomatous effusions. <i>European Journal of Cancer</i> , <b>1996</b> , 32A, 555-6	7.5	21
51	Diagnostic and prognostic implications of genetic lesions in non-hodgkin's lymphoma. <i>European Journal of Cancer</i> , <b>1996</b> , 32A, 1477-82	7.5	
50	Potential heterosexual Kaposi's sarcoma-associated herpesvirus transmission in a couple with HIV-induced immunodepression and with Kaposi's sarcoma and multicentric Castleman's disease. <i>Aids</i> , <b>1996</b> , 10, 1291-2	3.5	7
49	Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. <i>Aids</i> , <b>1996</b> , 10, 941-9	3.5	67
48	AIDS-related non-Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. <i>Acta Haematologica</i> , <b>1996</b> , 95, 193-8	2.7	24
47	Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome. <i>Leukemia Research</i> , <b>1996</b> , 20, 441-3	2.7	15
46	Centromeric instability of chromosome 1 resulting in multibranching chromosomes, telomeric fusions, and "jumping translocations" of 1q in a human immunodeficiency virus-related non-Hodgkin's lymphoma. <i>Cancer</i> , <b>1996</b> , 78, 1142-4	6.4	10
45	Structural abnormality of 1q in an AIDS-related body-cavity-based lymphoma. <i>International Journal of Cancer</i> , <b>1996</b> , 67, 588-90	7.5	7
44	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. <i>Genes Chromosomes and Cancer</i> , <b>1996</b> , 15, 48-53	5	9
43	Molecular heterogeneity of B-lineage diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , <b>1996</b> , 16, 21-30	5	30
42	Analysis of microsatellite instability in chronic lymphoproliferative disorders. <i>Annals of Hematology</i> , <b>1996</b> , 72, 67-71	3	29
41	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. <i>British Journal of Haematology</i> , <b>1996</b> , 94, 533-43	4.5	176
40	Aids-Related Non-Hodgkin Lymphomas <b>1996</b> , 277-284		
39	Cellular origin, antigen reactivity, and VH segment structure of IgM mAbs from AIDS lymphomas. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 764, 509-18	6.5	7

38	Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. <i>Clinical Immunology and Immunopathology</i> , <b>1995</b> , 75, 26-32		57
37	Molecular pathogenesis of AIDS-related lymphomas. <i>Advances in Cancer Research</i> , <b>1995</b> , 67, 113-53	5.9	53
36	AIDS-related Burkitt's lymphoma. Morphologic and immunophenotypic study of biopsy specimens. <i>American Journal of Clinical Pathology</i> , <b>1995</b> , 103, 561-7	1.9	70
35	High frequency of CD45RO expression in AIDS-related B-cell non-Hodgkin's lymphomas. <i>American Journal of Clinical Pathology</i> , <b>1995</b> , 104, 680-8	1.9	9
34	AIDS-related lymphomas: from pathogenesis to pathology. <i>British Journal of Haematology</i> , <b>1995</b> , 90, 235-43	4.5	46
33	Distribution of Kaposi's sarcoma herpesvirus sequences among lymphoid malignancies in Italy and Spain. <i>British Journal of Haematology</i> , <b>1995</b> , 91, 918-20	4.5	77
32	High frequency of EBV association with non-random abnormalities of the chromosome region 1q21-25 in AIDS-related Burkitt's lymphoma-derived cell lines. <i>International Journal of Cancer</i> , <b>1995</b> , 61, 370-4	7.5	21
31	Diffuse large cell lymphomas exhibit frequent deletions in 9p21-22 and 9q31-34 regions. <i>Genes Chromosomes and Cancer</i> , <b>1995</b> , 12, 32-6	5	27
30	Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. <i>Genes Chromosomes and Cancer</i> , <b>1995</b> , 14, 106-11	5	25
29	Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments. <i>Blood</i> , <b>1994</b> , 83, 2952-2961	2.2	65
28	Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. <i>Blood</i> , <b>1994</b> , 84, 883-888	2.2	77
27	Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. <i>Blood</i> , <b>1994</b> , 84, 397-402	2.2	102
26	Molecular pathogenesis of AIDS-related lymphomas. <i>Antibiotics and Chemotherapy</i> , <b>1994</b> , 46, 117-24		4
25	Subregional mapping of 8 single copy loci to chromosome 6 by fluorescence in situ hybridization. <i>Cytogenetic and Genome Research</i> , <b>1994</b> , 66, 272-3	1.9	14
24	Identification of genetic lesions associated with diffuse large-cell lymphoma. <i>Annals of Oncology</i> , <b>1994</b> , 5 Suppl 1, 55-60	10.3	50
23	Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , <b>1994</b> , 68, 3-7	3	35
22	Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. <i>Annals of Hematology</i> , <b>1994</b> , 69, 281-90	3	24
21	Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. <i>Genes Chromosomes and Cancer</i> , <b>1994</b> , 9, 13-8	5	27

20	A 2-Mb YAC contig linking the plasminogen-apoprotein(a) gene family to the insulin-like growth factor 2 receptor (IGF2R) gene on the telomeric region of chromosome 6 (6q26-q27). <i>Genomics</i> , <b>1994</b> , 22, 664-6	4.3	8
19	Subregional localization of 20 single-copy loci to chromosome 6 by fluorescence in situ hybridization. <i>Genomics</i> , <b>1993</b> , 16, 426-30	4.3	24
18	Molecular defects associated with the acute phase CML. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 11 Suppl 1, 25-8.	9	16
17	Biologic and molecular characterization of non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , <b>1993</b> , 5, 776-84	4.2	34
16	p53 mutations are associated with histologic transformation of follicular lymphoma. <i>Blood</i> , <b>1993</b> , 82, 2289-2295	2.2	294
15	Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. <i>FASEB Journal</i> , <b>1993</b> , 7, 951-6	0.9	32
14	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , <b>1993</b> , 81, 166-176	2.2	174
13	PvuII RFLP in the cytovillin gene (VIL2) on human chromosome 6q. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 1158-1158	1	158
12	Biologic aspects of human immunodeficiency virus-related lymphoma. <i>Current Opinion in Oncology</i> , <b>1992</b> , 4, 900-6	4.2	27
11	A new TaqI polymorphism in the p53 gene. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 928	20.1	26
10	Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. <i>Blood</i> , <b>1992</b> , 79, 2981-2989	2.2	185
9	Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. <i>Blood</i> , <b>1992</b> , 80, 1781-1787	7	130
8	Na <sup>+</sup> /H <sup>+</sup> antiporter has different properties in human B lymphocytes according to CD5 expression and malignant phenotype. <i>European Journal of Immunology</i> , <b>1991</b> , 21, 583-8	6.1	10
7	SacI RFLP in the insulin-like growth factor 2 receptor gene (IGF2R) on human chromosome 6q. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 6974	20.1	1
6	p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 5413-7	11.5	691
5	'Role of bone marrow stromal cells in the growth of human multiple myeloma. <i>Blood</i> , <b>1991</b> , 77, 2688-2693	2	3
4	Circulating malignant precursors in monoclonal gammopathies. <i>European Journal of Haematology</i> , <b>1989</b> , 51, 27-9	3.8	1
3	Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. <i>Journal of Experimental Medicine</i> , <b>1989</b> , 170, 613-8	16.6	142

2	Human normal CD5+ B lymphocytes can be induced to differentiate to CD5- B lymphocytes with germinal center cell features. <i>Blood</i> , <b>1989</b> , 73, 1259-1263	2.2	2
1	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> ,	1.3	0